COMPUTER SIMULATION OF THE COMBINED USE OF AZATHIOPRINE WITH METHYLPREDNISOLONE UNDER THE CONDITIONS OF PHARMACOTHERAPY OF MYASTHENIA GRAVIS

Authors:

Abstract:

The combined use of physiologically active compounds is aimed at optimizing their combined pharmacotherapeutic effect, which provides for reducing adverse reactions of ingredients, reducing their doses under conditions of potential synergism of the used components and increasing the convenience of taking ready-made medicinal forms. The purpose of this study was to assess the possibility of combined use, effectiveness and safety of azathioprine and methylprednisolone in the treatment of myasthenia gravis. Possible chemical reactions of the compounds were predicted based on the presence and reactivity of the functional groups included in their structure. The analysis of the acid-base properties of the compounds was carried out using the ACD/pKaDB and ChemAxon programs. Analysis of physicochemical properties and data on the interaction with enzyme systems for methylprednisolone and azathioprine suggests the absence of possible interactions between these drugs at the chemical and pharmacokinetic levels (with the need to adjust dosage regimens). At the pharmacological level, the combined therapeutic effect of methylprednisolone and azathioprine is expected to contribute to more effective treatment of multiple sclerosis by inhibiting the development and course of inflammatory reactions.

Keywords:

myasthenia gravis computer modelling pharmacotherapy combined effect methylprednisolone azathioprine treatment

References:

1. Aljumah AA, Al Jarallah B, Albenmousa A, Al Khathlan A, Al Zanbagi A, Al Quaiz M, et al. The Saudi association for the study of liver diseases and transplantation clinical practice guidelines for management of autoimmune hepatitis. Saudi J Gastroenterol. 2018;24(7 Suppl):1–20. doi:10.4103/sjg.SJG_159_18
2. Chang H, Tang TC, Hung YS, Li PL, Kuo MC, Wu JH, et al. Immune thrombocytopenia: Effectiveness of frontline steroids and comparison of azathioprine, splenectomy, and rituximab as second-line treatment. Eur J Haematol. 2018;101(4):549–555. doi:10.1111/ejh.13144
3. Chen Y, Tao X, Wang Y, Xu S, Yang Y, Han J et al. Clinical Characteristics and Prognosis of Anti-AChR Positive Myasthenia Gravis Combined With Anti-LRP4 or Anti-Titin Antibody. Frontiers in Neurology. 2022;13. Doi: 10.3389/fneur.2022.873599
4. Chou C, Su I, Chou I, Lin J, Lan S, Wang Y et al. Correlation of anti-acetylcholine receptor antibody levels and long-term outcomes of juvenile myasthenia gravis in Taiwan: a case control study. BMC Neurology. 2019;19(1). Doi: 10.1186/s12883-019-1397-0
5. Dresser L, Wlodarski R, Rezania K, Soliven B. Myasthenia Gravis: Epidemiology, Pathophysiology and Clinical Manifestations. Journal of Clinical Medicine. 2021;10(11):2235. Doi: 10.3390/jcm10112235
6. Kalbus O, Nefodov O. The role of antibodies to acetylcholine, muscle-specific kinase, titin and sox1 receptors in predicting severe myasthenia gravis. World of Medicine and Biology. 2022;18(80):74. DOI: 10.26724/2079-8334-2022-2-80-74-78
7. Ladrière M. Indications actuelles de l'azathioprine en néphrologie [Current indications of azathioprine in nephrology]. Nephrol Ther. 2013;9(1):8–12. doi:10.1016/j.nephro.2012.08.002
8. Masaki Y, Nakase H, Tsuji Y, Nojima M, Shimizu K, Mizuno N, et al. The clinical efficacy of azathioprine as maintenance treatment for autoimmune pancreatitis: a systematic review and meta-analysis. J Gastroenterol. 2021;56(10):869–880. doi:10.1007/s00535-021-01817-9
9. Mathian A, Jouenne R, Chader D, Cohen-Aubart F, Haroche J, Fadlallah J, et al. Regulatory T Cell Responses to High-Dose Methylprednisolone in Active Systemic Lupus Erythematosus. PLoS One. 2015; 10(12):e0143689. doi: 10.1371/journal.pone.0143689.
10. Narayanaswami P, Sanders D, Wolfe G, Benatar M, Cea G, Evoli A et al. International Consensus Guidance for Management of Myasthenia Gravis. Neurology. 2020;96(3):114–122.
11. National Center for Biotechnology Information (2022). PubChem Compound Summary for CID 6741, Methylprednisolone. Retrieved September 12, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Methylprednisolone.
12. National Center for Biotechnology Information. PubChem Compound Summary for CID 2265, Azathioprine. Retrieved September 8, 2022 from https://pubchem.ncbi.nlm.nih.gov/compound/Azathioprine.
13. Patel AA, Swerlick RA, McCall CO. Azathioprine in dermatology: the past, the present, and the future. J Am Acad Dermatol. 2006;55(3):369–389. doi:10.1016/j.jaad.2005.07.059
14. Schmidt C., Herrlinger K., Siegmund B., Bokemeyer B., Schreiber S., Stallmach A., et al. Azathioprin in der Therapie des Morbus Crohn--eine Standortbestimmung vor dem Hintergrund aktueller Studien [Azathioprine in Crohn's disease therapy--guidance against the background of recent studies]. Z Gastroenterol. 2014;52(12):1423–1430. doi:10.1055/s-0034-1385650
15. Sheiko MA, Sundaram SS, Capocelli KE, Pan Z, McCoy AM, Mack CL. Outcomes in Pediatric Autoimmune Hepatitis and Significance of Azathioprine Metabolites. J Pediatr Gastroenterol Nutr. 2017;65(1):80–85. doi:10.1097/MPG.0000000000001563

Publication:

«World of Medicine and Biology» Vol. 18 No. 81 (2022) , с. 88-93
УДК 616-004-031-085:615.37+615.357:004.94

DOI:

https://doi.org/10.26724/2079-8334-2022-3-81-88-93